FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry and is an oral preparation for controlling endoparasites in humans or animals comprising emoepside in an amorphous state in a polyvinylpyrrolidone matrix in the form of a melt extrudate or co-precipitate.
EFFECT: invention provides an unexpectedly high improvement in solubility and bioavailability.
8 cl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING AMORPHOUS EMODEPSID | 2012 |
|
RU2761529C2 |
| SUSTAINED RELEASE SOLID THERAPEUTIC AGENT | 2009 |
|
RU2548733C9 |
| ENDOPARASITICIDAL DRUG | 2006 |
|
RU2417101C2 |
| ANTHELMINTIC AGENTS COMBINATIONS AND METHODS FOR USE THEREOF | 2016 |
|
RU2717545C2 |
| PHARMACEUTICAL PREPARATION AND ITS PRODUCTION METHOD | 2017 |
|
RU2764849C2 |
| CRYSTALLINE MODIFICATION OF CYCLIC DEPSIPEPTIDE OF IMPROVED ACTIVITY | 2002 |
|
RU2300390C2 |
| NIFURTIMOX FOR TREATING DISEASES CAUSED BY TRICHOMONADIDA | 2009 |
|
RU2538712C2 |
| NEW INJECTABLE COMPOSITIONS OF EPRINOMECTIN | 2011 |
|
RU2578036C2 |
| ANTIPARASITIC COMPOUNDS WITH AN APPEALING FLAVOUR | 2019 |
|
RU2773154C1 |
| ENDOPARASITIC AGENT | 2000 |
|
RU2250779C2 |
